Does higher hs-CRP reflect low-grade inflammation and higher cardiovascular risk?

Higher hs-CRP is a well-established nonspecific indicator of systemic inflammation and a clinically relevant adjunct marker of cardiovascular risk. Its relation to endothelial dysfunction is biologically credible but less consistent in human population studies.

Inflammation and cardiovascular risk

• hs-CRP measures circulating C-reactive protein, a hepatic acute-phase reactant produced chiefly in response to IL-6, with IL-1 and TNF contributing. In stable individuals, a persistent modest elevation therefore reflects low-grade systemic inflammatory activity, although not its source or tissue location.
• Prospective data support an association with future ASCVD events. In ARIC, hs-CRP ≥2.4 mg/L predicted incident ASCVD (adjusted hazard ratios 1.33–1.47); in UK Biobank, hs-CRP >3 versus <1 mg/L was associated with 34% higher major adverse cardiovascular-event risk.
• Clinically, ACC/AHA recognizes hs-CRP ≥2.0 mg/L as an ASCVD risk-enhancing factor. Its incremental predictive performance is modest: a review of 31 prospective cohorts reported AUCs around 0.57–0.59, with small and inconsistent reclassification gains.

Endothelial biology

• A mechanistic pathway is plausible: CRP-associated oxidative stress, NADPH-oxidase activation, eNOS uncoupling, and altered eNOS regulation may reduce nitric-oxide bioavailability. In coronary artery disease, higher CRP independently predicted lower basal and stimulated systemic nitric-oxide availability.
• However, the epidemiologic association with flow-mediated dilation is heterogeneous. MESA (n=3,501) found no adjusted CRP–FMD association (r=0.008; P=0.64), whereas associations were more evident in chronic kidney disease, renal-transplant, and claudication populations.

Practical interpretation

• Exclude acute infection, trauma, or active inflammatory disease. Repeat testing during metabolic stability is appropriate; hs-CRP ≥10 mg/L warrants evaluation for an acute or occult inflammatory cause.

Bottom line

• For this 71-year-old man, persistently elevated hs-CRP supports low-grade inflammation and modestly higher cardiovascular risk, but it should refine—not replace—global cardiovascular risk assessment.